You just read:

New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

May 05, 2018, 08:00 ET